2746 A Phase 2 open-label, multicenter study of single-agent rucaparib in the treatment of patients with relapsed ovarian cancer and a deleterious BRCA mutation. (September 2015) - Shapira-Frommer, R.; Oza, A.; Domchek, S.M.; Balmana, J.; Patel, M.R.; Chen, L.M.; Drew, Y.; Burris, H.A.; Korach, J.; Flynn, M.; Bowering, V.L.; Morgan, M.A.; et al.